Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with rendu‐osler disease
- 23 March 2012
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 122 (5), 953-955
- https://doi.org/10.1002/lary.23230
Abstract
Objectives/Hypothesis: To evaluate the efficacy and safety of bevacizumab administered at a concentration of 50 mg as an intranasal spray in the treatment of epistaxis in patients suffering from Rendu‐Osler disease. Study Design: Prospective. Methods: A preliminary, prospective, review board‐approved study was conducted on six patients with Rendu‐Osler disease who received 10 treatment courses of 50 mg bevacizumab. Monthly follow‐up was based on the epistaxis severity score (ESS), with adverse effects being reported. Results: Ten treatment courses were administered to six patients, with a mean follow‐up period of 2.8 months. A statistically significant decrease in mean ESS was observed at 1 month (P < .001) and 2 months (P < .005), whereas a nonsignificant decrease was found at 3 months (P = .07). A nonsignificant decline in mean ESS was detected at 1 month in patients with ESS ≥7 at baseline. No adverse effects were reported. Conclusions: The intranasal spray application of 50 mg bevacizumab was found to be an effective symptomatic treatment over a period of 2 months for patients with a pretreatment ESS of <7, with no adverse effects being noted.Keywords
This publication has 13 references indexed in Scilit:
- Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question.Recent Patents on Inflammation & Allergy Drug Discovery, 2012
- Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia‐associated epistaxisThe Laryngoscope, 2010
- Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia‐associated epistaxisThe Laryngoscope, 2010
- An epistaxis severity score for hereditary hemorrhagic telangiectasiaThe Laryngoscope, 2010
- Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration: A Multicenter, Retrospective StudyOphthalmology, 2010
- Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumabAnnals of Hematology, 2006
- The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro‐Caribbean population of the Netherlands Antilles: A family screeningAmerican Journal of Medical Genetics Part A, 2002
- Hereditäre hämorrhagische Teleangiektasie (Morbus Osler)HNO, 2002
- Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)American Journal of Medical Genetics, 2000
- Hereditary Hemorrhagic TelangiectasiaThe New England Journal of Medicine, 1995